Ultragenyx Pharmaceutical Inc. (RARE): A Bull Case Theory

We came crossed a bullish thesis connected Ultragenyx Pharmaceutical Inc. connected HalfBakedInnovations’s Substack by Biotech Distilled. In this article, we volition summarize the bulls’ thesis connected RARE. Ultragenyx Pharmaceutical Inc.'s stock was trading astatine $23.88 arsenic of February 9th.

M. A. Arkhipov/Shutterstock.com

Ultragenyx Pharmaceuticals positions itself arsenic a diversified uncommon illness institution with 4 approved products generating astir $670 cardinal successful yearly revenue, but the caller Phase 3 nonaccomplishment of setrusumab—where bony density improved without reducing fractures—highlights a halfway risk: biomarker occurrence does not warrant objective benefit. The institution present faces a pivotal 2026 defined by 2 cistron therapy PDUFA decisions (UX111 for Sanfilippo A and DTX401 for GSDIa in Q3 2026) and Phase 3 information for GTX-102 successful Angelman syndrome successful H2 2026.

Scientifically, the pipeline is credible. UX111 uses an AAV9 self-complementary vector to present SGSH crossed the blood-brain barrier, relying connected cross-correction to trim heparan sulfate and sphere cognition. DTX401 employs AAV8 to reconstruct G6Pase enactment successful the liver, with Phase 3 information showing cornstarch simplification improving from 41% astatine Week 48 to 61% astatine Week 96, supporting durability. GTX-102, an intrathecal antisense oligonucleotide, aims to unsilence the paternal UBE3A cistron successful Angelman syndrome, straight targeting illness biology, though little limb weakness underscores a constrictive therapeutic window.

Financially, however, the institution burned astir $446 cardinal successful the archetypal 9 months of 2025, implying an annualized ~$600 cardinal pain against ~$735 cardinal successful cash—about 1.2 years of runway—creating meaningful dilution hazard up of catalysts. Manufacturing remains the plaything origin aft UX111’s anterior CRL for CMC issues. Intellectual spot is mixed: cistron therapies payment from method barriers, GTX-102 has runway to ~2037, but Crysvita is licensed and Dojolvi faces progressive generic challenges. Ultragenyx is frankincense a binary 2026 communicative masked arsenic diversification, with approvals and cleanable Angelman information determining whether it rerates oregon raises superior from weakness.

Previously, we covered a bullish thesis on AbbVie Inc. (ABBV) by Magnus Ofstad successful May 2025, which highlighted the spot of its immunology franchise, Elahere’s clinical success, disciplined superior allocation, and pipeline-led maturation offsetting Humira erosion. ABBV’s banal terms has appreciated by astir 12.49% since our coverage. Biotech Distilled shares a akin outlook but emphasizes Ultragenyx’s cistron therapy-driven 2026 catalysts and binary regulatory hazard alternatively than diversified commercialized strength.